Table 2.
All (N = 8610) |
Alirocumab (N = 4305) |
Placebo (N = 4305) |
|
---|---|---|---|
Age, years | 58.5 (9.3) | 58.6 (9.2) | 58.4 (9.4) |
< 65 years | 6335 (73.6%) | 3165 (73.5%) | 3170 (73.6%) |
65 to < 75 years | 1822 (21.2%) | 911 (21.2%) | 911 (21.2%) |
≥ 75 years | 453 (5.3%) | 229 (5.3%) | 224 (5.2%) |
Male | 6973 (81.0%) | 3478 (80.8%) | 3495 (81.2%) |
Race | |||
White | 6563 (76.2%) | 3262 (75.8%) | 3301 (76.7%) |
Asian | 1436 (16.7%) | 734 (17.0%) | 702 (16.3%) |
Other/unknown | 611 (7.1%) | 309 (7.3%) | 302 (7.0%) |
Hispanic or Latino | 1680 (19.5%) | 858 (19.9%) | 822 (19.1%) |
Weight, kg | 82.02 (16.68) | 81.88 (16.69) | 82.17 (16.68) |
BMI, kg/m2 | 28.29 (4.68) | 28.30 (4.70) | 28.28 (4.66) |
≥ 30 kg/m2 | 2721 (31.8%) | 1344 (31.4%) | 1377 (32.1%) |
Region | |||
Asia | 1359 (15.8%) | 689 (16.0%) | 670 (15.6%) |
South America | 1443 (16.8%) | 734 (17.0%) | 709 (16.5%) |
Eastern Europe | 2290 (26.6%) | 1124 (26.1%) | 1166 (27.1%) |
Western Europe | 1869 (21.7%) | 921 (21.4%) | 948 (22.0%) |
North America | 1088 (12.6%) | 55 (12.9%) | 534 (12.4%) |
Rest of world | 561 (6.5%) | 283 (6.6%) | 278 (6.5%) |
Data are presented as mean ± standard deviation or n (%)
BMI Body mass index